{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:02:27Z","timestamp":1792839747650,"version":"4.5.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T00:00:00Z","timestamp":1731542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T00:00:00Z","timestamp":1731542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Merck Sharp & Dohme Spain"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"DOI":"10.1186\/s12889-024-20625-3","type":"journal-article","created":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T09:59:44Z","timestamp":1731578384000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Rate of hepatitis C reinfection after successful direct-acting antivirals treatment among people who inject drugs in Spain: the LIVERate study"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-4023-2646","authenticated-orcid":false,"given":"Fernando","family":"Chac\u00f3n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Morano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Granados","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep M\u00aa","family":"Llibre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Ald\u00e1miz-Echevarria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luz Mart\u00edn","family":"Carbonero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Puigveh\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imma","family":"Clotet-Codina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Sanchez-Vega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Vacas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Rinc\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Berenguer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Crespo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Roncero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,14]]},"reference":[{"key":"20625_CR1","unstructured":"World Health Organization (WHO) [internet], Hepatitis C. May. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c. Last access 2023."},{"issue":"5","key":"20625_CR2","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1111\/jvh.13480","volume":"28","author":"L Krekulova","year":"2021","unstructured":"Krekulova L, Honz\u00e1k R, Riley LW. Viral hepatitis C pandemic: challenges and threats to its elimination. J Viral Hepat. 2021;28(5):694\u20138.","journal-title":"J Viral Hepat"},{"key":"20625_CR3","doi-asserted-by":"publisher","first-page":"100038","DOI":"10.1016\/j.dadr.2022.100038","volume":"3","author":"A Viera","year":"2022","unstructured":"Viera A, Grau LE, Fisher JD, Farnum SO, Tetrault JM, Scott G, Heimer R. Development and pilot-testing of a hepatitis C reinfection prevention intervention for patients in treatment for hepatitis C infection. Drug Alcohol Depend Rep. 2022;3:100038.","journal-title":"Drug Alcohol Depend Rep"},{"key":"20625_CR4","unstructured":"de Sanidad M. Servicios Sociales e Igualdad [internet]. Plan estrat\u00e9gico para el abordaje de la hepatitis C en el Sistema Nacional de Salud (PEAHC); 2015. https:\/\/www.sanidad.gob.es\/ciudadanos\/enfLesiones\/enfTransmisibles\/hepatitisC\/PlanEstrategicoHEPATITISC\/docs\/plan_estrategico_hepatitis_C.pdf. Last access May 2023."},{"issue":"0","key":"20625_CR5","first-page":"1743","volume":"0","author":"J Colom","year":"2022","unstructured":"Colom J, Torrens M, Rodr\u00edguez-Cejas \u00c1, Aguilar I, \u00c1lvarez-Crespo R, Armenteros L, et al. Certification program of Addiction centres for Hepatitis C virus elimination in Spain. HepCelentes Project Adicciones. 2022;0(0):1743.","journal-title":"HepCelentes Project Adicciones"},{"issue":"14","key":"20625_CR6","doi-asserted-by":"publisher","first-page":"4951","DOI":"10.3390\/ijerph17144951","volume":"17","author":"A Muller","year":"2020","unstructured":"Muller A, Vlahov D, Akiyama MJ, Kurth A. Hepatitis C reinfection in people who inject drugs in resource-limited countries: a systematic review and analysis. Int J Environ Res Public Health. 2020;17(14):4951.","journal-title":"Int J Environ Res Public Health"},{"issue":"1","key":"20625_CR7","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s12954-021-00552-x","volume":"18","author":"D Busschots","year":"2021","unstructured":"Busschots D, Bielen R, Koc \u00d6M, Heyens L, Verrando R, de Galocsy C, et al. Hepatitis C reinfection in former and active injecting drug users in Belgium. Harm Reduct J. 2021;18(1):102.","journal-title":"Harm Reduct J"},{"key":"20625_CR8","doi-asserted-by":"crossref","unstructured":"Hibbert M, Simmons R, Harris H, Desai M, Sabin CA, Mandal S. Investigating rates and risk factors for hepatitis C virus reinfection in people receiving antiviral treatment in England. J Viral Hepat. 2023.","DOI":"10.1111\/jvh.13835"},{"key":"20625_CR9","unstructured":"Guidelines for the care and treatment of persons diagnosed with chronic Hepatitis C virus infection [internet]. Geneva: World Health Organization. 2018, Public Health Considerations for Specific Populations. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK531722\/. Last access May 2023."},{"issue":"6","key":"20625_CR10","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1093\/cid\/civ948","volume":"62","author":"B Simmons","year":"2016","unstructured":"Simmons B, Saleem J, Hill A, Riley RD, Cooke GS. Risk of late relapse or reinfection with Hepatitis C virus after achieving a sustained virological response: a systematic review and meta-analysis. Clin Infect Dis. 2016;62(6):683\u201394.","journal-title":"Clin Infect Dis"},{"key":"20625_CR11","doi-asserted-by":"crossref","first-page":"752A","DOI":"10.1002\/hep.26372","volume":"58","author":"A Mangia","year":"2013","unstructured":"Mangia A, Kugelmas M, Everson GT, Hinestrosa F, Ma J, McNally J, et al. Virologic response rates to sofosbuvir-containing regimens are similar in patients with and without traditional negative predictive factors: a retrospective analysis of phase 3 data. Hepatology. 2013;58:752A.","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"20625_CR12","first-page":"a1141","volume":"60","author":"IM Jacobson","year":"2014","unstructured":"Jacobson IM, Kwo PY, Kowdley KV, Yang JC, Zhu Y, Hyland RH, et al. Virologic response rates to all oral fixed-dose combination ledipasvir\/sofosbuvir regimens are similar in patients with and without traditional negative predictive factors in phase 3 clinical trials. Hepatology. 2014;60(Suppl 1):a1141\u20132.","journal-title":"Hepatology"},{"key":"20625_CR13","doi-asserted-by":"crossref","first-page":"a1135","DOI":"10.1002\/hep.27052","volume":"60","author":"M Puoti","year":"2014","unstructured":"Puoti M, Cooper C, Sulkowski MS, Foster GR, Berg T, Villa E, et al. ABT-450\/r\/ombitasvir plus dasabuvir with or without Ribavirin in HCV genotype 1\u2010infected patients receiving stable opioid substitution treatment: pooled analysis of efficacy and safety in phase 2 and phase 3 trials. Hepatology. 2014;60:a1135\u20136.","journal-title":"Hepatology"},{"issue":"3","key":"20625_CR14","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1111\/jvh.12859","volume":"25","author":"O Falade-Nwulia","year":"2018","unstructured":"Falade-Nwulia O, Sulkowski MS, Merkow A, Latkin C, Mehta SH. Understanding and addressing hepatitis C reinfection in the oral direct-acting antiviral era. J Viral Hepat. 2018;25(3):220\u20137.","journal-title":"J Viral Hepat"},{"key":"20625_CR15","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jsat.2019.04.009","volume":"102","author":"N Williams","year":"2019","unstructured":"Williams N, Bossert N, Chen Y, Jaanimagi U, Markatou M, Talal AH. Influence of social determinants of health and substance use characteristics on persons who use drugs pursuit of care for hepatitis C virus infection. J Subst Abuse Treat. 2019;102:33\u20139.","journal-title":"J Subst Abuse Treat"},{"issue":"9","key":"20625_CR16","doi-asserted-by":"publisher","first-page":"625","DOI":"10.7326\/M16-0816","volume":"165","author":"GJ Dore","year":"2016","unstructured":"Dore GJ, Altice F, Litwin AH, Dalgard O, Gane EJ, Shibolet O, et al. Elbasvir- Grazoprevir to treat hepatitis c virus infection in persons receiving opioid agonist therapy: a randomized trial. Ann Intern Med. 2016;165(9):625\u201334.","journal-title":"Ann Intern Med"},{"issue":"9","key":"20625_CR17","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.7326\/M21-4119","volume":"175","author":"J Grebely","year":"2022","unstructured":"Grebely J, Dore GJ, Altice FL, Conway B, Litwin AH, Norton BL, et al. Reinfection and risk behaviors after treatment of hepatitis c virus infection in persons receiving opioid agonist therapy: a cohort study. Ann Intern Med. 2022;175(9):1221\u20139.","journal-title":"Ann Intern Med"},{"issue":"4","key":"20625_CR18","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.jhep.2019.11.012","volume":"72","author":"B Hajarizadeh","year":"2020","unstructured":"Hajarizadeh B, Cunningham EB, Valerio H, Martinello M, Law M, Janjua NZ, et al. Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: a meta-analysis. J Hepatol. 2020;72(4):643\u201357.","journal-title":"J Hepatol"},{"issue":"5","key":"20625_CR19","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.jhep.2018.07.025","volume":"69","author":"C Rossi","year":"2018","unstructured":"Rossi C, Butt ZA, Wong S, Buxton JA, Islam N, Yu A, BC Hepatitis Testers Cohort Team, et al. Hepatitis C virus reinfection after successful treatment with direct-acting antiviral therapy in a large population-based cohort. J Hepatol. 2018;69(5):1007\u201314.","journal-title":"J Hepatol"},{"key":"20625_CR20","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.jinf.2015.07.006","volume":"71","author":"JA Pineda","year":"2015","unstructured":"Pineda JA, N\u00fa\u00f1ez-Torres R, T\u00e9llez F, Mancebo M, Garc\u00eda F, Merchante N, et al. Hepatitis C virus reinfection after sustained virological response in HIV-infected patients with chronic hepatitis C. J Infect. 2015;71:571\u201377.","journal-title":"J Infect"},{"key":"20625_CR21","doi-asserted-by":"crossref","unstructured":"Beiser ME, Shaw LC, Shores SK, Carson JM, Hajarizadeh B. Hepatitis C virus reinfection in a real-world cohort of homeless-experienced individuals in Boston. Clin Infect Dis. 2023:ciad127.","DOI":"10.1093\/cid\/ciad127"},{"issue":"12","key":"20625_CR22","doi-asserted-by":"publisher","first-page":"100580","DOI":"10.1016\/j.jhepr.2022.100580","volume":"4","author":"S Lens","year":"2022","unstructured":"Lens S, Miralpeix A, G\u00e1lvez M, Martr\u00f3 E, Gonz\u00e1lez N, Rodr\u00edguez-Tajes S, et al. HCV microelimination in harm reduction centres has benefits beyond HCV cure but is hampered by high reinfection rates. JHEP Rep. 2022;4(12):100580.","journal-title":"JHEP Rep"},{"key":"20625_CR23","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1186\/1471-2458-12-1058","volume":"12","author":"C Strike","year":"2012","unstructured":"Strike C, Rudzinski K, Patterson J, Millson M. Frequent food insecurity among injection drug users: correlates and concerns. BMC Public Health. 2012;12:1058.","journal-title":"BMC Public Health"},{"key":"20625_CR24","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/9781119533481.ch18","volume-title":"Clinical dilemmas in viral liver disease","author":"J Grebely","year":"2020","unstructured":"Grebely J, Martinello M. Harm reduction strategies to prevent new infections and reinfections among people who inject drugs: how effective are they? In: Foster GR, Reddy KR, editors. Clinical dilemmas in viral liver disease. 2nd ed. Hoboken (NJ): Wiley-Blackwell; 2020. pp. 106\u201311.","edition":"2"},{"issue":"3","key":"20625_CR25","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.gastrohep.2022.06.005","volume":"46","author":"C Roncero","year":"2023","unstructured":"Roncero C, Buch-Vicente B, Mart\u00edn-S\u00e1nchez \u00c1M, \u00c1lvarez-Navares AI, Andr\u00e9s-Olivera P, Gamonal-Limcaoco S, et al. Prevalence of hepatitis C virus infection in patients with chronic mental disorders: the relevance of dual disorders. Gastroenterol Hepatol. 2023;46(3):171\u20137.","journal-title":"Gastroenterol Hepatol"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-024-20625-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-024-20625-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-024-20625-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T10:03:37Z","timestamp":1731578617000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-024-20625-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,14]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["20625"],"URL":"https:\/\/doi.org\/10.1186\/s12889-024-20625-3","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,14]]},"assertion":[{"value":"18 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in conformance with Good Clinical Practice standards and applicable to the Spanish and Autonomous Communities legal regulations regarding ethical committee review, informed consent, and the protection of human subjects participating in biomedical research. Vall d\u00b4Hebron University Hospital\u00b4s clinical research ethics committee approved this study on September 8th, 2017 and written informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"J.N. has received honoraria and\/or speaking fees and\/or financial support for attending conferences from Abbvie, Gilead, Janssen-Cilag, Merck Sharp & Dome, and ViiV Healthcare outside of the submitted work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3167"}}